Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Subscribe To Our Newsletter & Stay Updated